Biotherapies in large vessel vasculitis

被引：50
|
作者：
Ferfar, Y. [1 ]
Mirault, T. [2 ]
Desbois, A. C. [1 ]
Comarmond, C. [1 ]
Messas, E. [2 ]
Savey, L. [1 ]
Domont, F. [1 ]
Cacoub, P. [1 ]
Saadoun, D. [1 ]
机构：
[1] Univ Paris 06, Grp Hosp Pitie Salpetriere, AP HP,Serv Med Interne & Immunol Clin,DHU I2B, Ctr Reference Malad Autoimmunes & Syst Rares,Immu, Paris, France
[2] Grp Hosp HEGP, AP HP, Serv Med Vasc, Ctr Natl Reference Malad Vasc Rares, Paris, France
来源：
AUTOIMMUNITY REVIEWS | 2016年 / 15卷 / 06期
关键词：
Giant cell arteritis; Takayasu; Behcet's disease; Relapsing polychondritis; Biotherapy; GIANT-CELL ARTERITIS; REFRACTORY TAKAYASU ARTERITIS; PLACEBO-CONTROLLED TRIAL; NECROSIS FACTOR THERAPY; ANTI-TNF-ALPHA; RELAPSING POLYCHONDRITIS; BEHCETS-DISEASE; POLYMYALGIA-RHEUMATICA; EULAR RECOMMENDATIONS; SUSTAINED RESPONSE;
D O I：
10.1016/j.autrev.2016.02.012
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Giant cell arteritis (GCA) and Takayasu's arteritis (TA) are large vessel vasculitis (LW) and aortic involvement is not uncommon in Behcet's disease (BD) and relapsing polychondritis (RP). Glucocorticosteroids are the mainstay of therapy in LW. However, a significant proportion of patients have glucocorticoid dependance, serious side effects or refractory disease to steroids and other immunosuppressive treatments such as cyclophosphamide, azathioprine, mycophenolate mofetil and methotrexate. Recent advances in the understanding of the pathogenesis have resulted in the use of biological agents in patients with LW. Anti-tumor necrosis factor-alpha drugs seem effective in patients with refractory Takayasu arteritis and vascular BD but have failed to do so in giant cell arteritis. Preliminary reports on the use of the anti-IL6-receptor antibody (tocilizumab), in LW have been encouraging. The development of new biologic targeted therapies will probably open a promising future for patients with LW. (C) 2016 Elsevier B.V. All rights reserved.
引用
收藏
页码：544 / 551
页数：8
相关论文
共 50 条
  • [31] Large Vessel Vasculitis with Chronic Cough
    Kawashima, Atsushi
    Okumura, Hisatoshi
    Inaba, Satoshi
    INTERNAL MEDICINE, 2023, 62 (19) : 2927 - 2927
  • [32] DIAGNOSIS AND ASSESSMENT OF LARGE VESSEL VASCULITIS
    Luqmani, Raashid
    RHEUMATOLOGY, 2011, 50 : 24 - 24
  • [33] Emerging therapies in large vessel vasculitis
    Banerjee, Siwalik
    Stapleton, Philip P.
    Dasgupta, Bhaskar
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2016, 19 (08) : 741 - 746
  • [34] Venothromboembolism in Large Vessel Vasculitis.
    Bhavsar, Sankalp V.
    Khalidi, Nader A.
    Carette, Simon
    Cuthbertson, David
    Grayson, Peter C.
    Hoffmann, Gary S.
    Koening, Curry L.
    Langford, Carol A.
    McAlear, Carol
    Moreland, Larry
    Monach, Paul A.
    Pagnoux, Christian
    Seo, Philip
    Warrington, Kenneth J.
    Ytterberg, Steven R.
    Merkel, Peter A.
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S351 - S351
  • [35] Imaging diagnostics in large vessel vasculitis
    Schmidt, W. A.
    Hartung, W.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2019, 78 (09): : 847 - 858
  • [36] IgA vasculitis with large vessel involvement
    Harikrishnan, G.
    Jain, Neeraj
    Verma, Vikrant
    Agarwal, Vikas
    Misra, Durga Prasanna
    RHEUMATOLOGY, 2020, 59 (07) : 1790 - 1791
  • [37] Molecular imaging of large vessel vasculitis
    Regis, Claudine
    Abikhzer, Gad
    Harel, Francois
    Pelletier-Galarneau, Matthieu
    JOURNAL OF MEDICAL IMAGING AND RADIATION SCIENCES, 2024, 55 (02) : S10 - S16
  • [38] IMAGING IN THE DIAGNOSIS OF LARGE VESSEL VASCULITIS
    Schmidt, Wolfgang
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 20 - 21
  • [39] Imaging in large-vessel vasculitis
    Schmidt, Wolfgang A.
    Nielsen, Berit D.
    BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2020, 34 (06):
  • [40] CLINICAL DIAGNOSIS OF LARGE VESSEL VASCULITIS
    Cimmino, M. A.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 37 - 37
12345